Richard W. Olaussen
Papers
1
Total Citations
30
H-Index
1
About
Richard W. Olaussen has made pioneering contributions to cancer immunotherapy, with a primary focus on developing personalized dendritic cell (DC) vaccines for high-risk prostate cancer. His landmark 2021 first-in-man Phase I/II study, which has garnered 30 citations, demonstrated the safety and immunogenicity of an adjuvant DC vaccine administered after radical prostatectomy. This work addresses a critical unmet need: reducing biochemical relapse in patients who face noncurative disease progression despite surgery. Olaussen’s research bridges the gap between preclinical immunology and clinical application, offering a novel strategy to harness the patient’s own immune system against residual tumor cells. His findings have opened new avenues for adjuvant treatment in high-risk prostate cancer, potentially delaying or preventing recurrence. Beyond this seminal study, his broader portfolio explores vaccine design, immune monitoring, and the optimization of dendritic cell manufacturing. Olaussen’s work stands as a testament to the promise of personalized cancer vaccines, and his ongoing research continues to shape the landscape of immuno-oncology, inspiring both clinicians and translational scientists.
Research Focus
Key Achievements
Top Papers
- 1